At Sentinal4D, we believe patients battling cancer, neurodegenerative diseases, and chronic inflammatory syndromes deserve personalized therapeutics. We are deploying a biology-first, holistic approach with focus on phenotypic-based drug discovery.
By harnessing AI-powered 3D cell imaging, we are transforming drug discovery and development, accelerating the journey of groundbreaking treatments from lab to clinic.
By integrating deep learning with 3D and 4D morphological profiling, Sentinal4D provides a more holistic view of cellular biology, enabling sensitive phenotypic analysis.
This unique combination of technology and biological expertise sets us apart, offering insights that drive drug discovery, improve patient outcomes, and transform the future of personalised medicine.
Building on 20 years of experience in cutting edge cell biology research, we are world leaders in the cell omics space.
Geometric deep learning and multiple-instance learning for 3D cell-shape profiling
Characterization of proteome-size scaling by integrative omics reveals mechanisms of proliferation control in cancer
Environmentally dependent and independent control of 3D cell shape
Identification of clinically predictive metagenes that encode components of a network coupling cell shape to transcription by image-omics
Quantitative Morphological Signatures Define Local Signaling Networks Regulating Cell Morphology
Phosphorylation Networks Regulating JNK Activity in Diverse Genetic Backgrounds
By
Chris Bakal
AI is transforming drug discovery, but the quality of its data is often overlooked, leading to biased predictions and missed opportunities.
Read More
Supported by
